OVA-E1 peptide (TFA)

• Description :

  OVA-E1 peptide TFA, is an antagonist variant of SIINFEKL [OVA (257-264) . OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes[1].

• UNSPSC :

  12352209

• Target :

  JNK; p38 MAPK

• Type :

  Peptides

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/ova-e1-peptide-tfa.html

• Purity :

  98.03

• Solubility :

  H2O

• Smiles :

  O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N.OC(C(F)(F)F)=O

• Molecular Formula :

  C49H77F3N10O16

• Molecular Weight :

  1119.19

• References & Citations :

  [1]Leandro J Carreño, et al. The Half-Life of the T-cell receptor/peptide-major Histocompatibility Complex Interaction Can Modulate T-cell Activation in Response to Bacterial Challenge. Immunology. 2007 Jun;121 (2) :227-37.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -80°C, 2 years; -20°C, 1 year (Powder, stored under nitrogen, away from moisture)

• Scientific Category :

  Peptides

• Clinical Information :

  No Development Reported

• CAS Number :

  [1262750-80-0]